The Manila Times

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and ...

Roche's Genentech Reports Positive Phase 3 Data for Autoimmune Disorder Treatment

Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint. Genentech said ...
Seeking Alpha

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Results in a population of 278 patients affirm statistically significant mortality reductions Benefits observed across severity groups and in subjects with serious comorbidities Company files ...
Seeking Alpha

Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect

Ocular Therapeutix targets retinal diseases, focusing on wet age-related macular degeneration (AMD) with its lead candidate, AXPAXLI (OTX-TKI). Current wet AMD treatment is dominated by anti-VEGF ...